EurekAlert (press release)Scientists create stem cell therapy for lung fibrosis conditionsEurekAlert (press release)CHAPEL HILL, NC – A team of scientists from the UNC School of Medicine and North Carolina State University (NCSU) has developed promisin… Continue reading
|
Medigene: Transition To Prominent Immunotherapy Player
Investing.com Medigene’s (DE:MDG1k) H1 results are in line with our expectations and represent the completion of its transformation into a prominent T-cell immunotherapy player. Highlights from H1 include submission of a clinical trial authorisation (CTA) to begin … |
|
Healing Osteoarthritis with Stem Cells
Anti Aging News Emory Orthopaedics and Spine Center physicians made waves five years ago when they launched regenerative stem cell therapy. This is a form of treatment for OA as well as related joint maladies. It makes use of the patient’s stem cells to remedy damaged … |
|
Allergy Immunotherapy Market Foreseen to Draw USD 4324.7 Million by 2023 at 10.85% of CAGR: Declares MRFR
Markets Insider PUNE, India, Aug. 3, 2017 /PRNewswire/ — Market Research Future published a Cooked research report on “Global Allergy Immunotherapy Market Research Report – Forecast to 2023″ – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Sublingual Allergy Immunotherapy Market Foreseen to Grow Exponentially Over 2017 – 2025satPRnews (press release) |
|
Allergy Immunotherapy Market Foreseen to Draw USD 4324.7 Million by 2023 at 10.85% of CAGR: Declares MRFR
Markets Insider PUNE, India, Aug. 3, 2017 /PRNewswire/ — Market Research Future published a Cooked research report on “Global Allergy Immunotherapy Market Research Report – Forecast to 2023″ – Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Sublingual Allergy Immunotherapy Market Foreseen to Grow Exponentially Over 2017 – 2025satPRnews (press release) |
|
European Patent Office to Grant MilliporeSigma’s Patent Application for CRISPR Technology
Canada NewsWire (press release) BILLERICA, Mass., Aug. 3, 2017 /CNW/ — MilliporeSigma today announced that the European Patent Office (EPO) has issued a “Notice of Intention to Grant” for MilliporeSigma’s patent application covering the company’s CRISPR technology used in a … |